The South African Health Products Regulatory Authority (SAHPRA) has expressed concern at the increasing presence of counterfeit Glucagon-like Peptide (GLP-1) products, such as Ozempic, on the local ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

A study reveals racial and ethnic disparities in access to Novo Nordisk's diabetes and weight loss drugs among U.S. military veterans. Black, Asian, and Native American patients are less likely to ...

U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk's highly in-demand drugs for diabetes and weight loss, according to a review of patient data published on Monday, the ...

In September, the company officially relocated its headquarters from a 114,000-square-foot space in New York City to a ...

Conditions are getting a bit more challenging for the drugmaker.

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Novo Nordisk's involve the GLP-1 pathway, while Eli Lilly's treatments activate both GLP-1 and GIP, known as dual GLP-1/GIP ...

A 58-year-old nurse from Scotland has died after taking two doses of weight-loss drug tirzepatide, also known as Mounjaro or ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.